A Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in AIS Subjects (BRIGHT)

A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in Subjects With Acute Ischemic Stroke (AIS)

This is a phase II, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of multiple doses of LT3001 drug product in subjects with acute ischemic stroke (AIS)

Study Overview

• Status: Completed
• Conditions: Acute Ischemic Stroke
• Intervention / Treatment: Drug: Placebo; Drug: LT3001 Drug Product

Detailed Description

This is a multicenter, double-blind, randomized, and placebo-controlled prospective Phase II clinical study, designed to evaluate LT3001 drug product versus placebo in subjects with AIS. The study is planned to take place in multiple countries. Subjects who participate in this trial should be treated with standard of care of AIS therapies when appropriate.

• Study Type: Interventional
• Enrollment (Actual): 89
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Tennessee
    • Chattanooga, Tennessee, United States, 37403
      • Chattanooga Center for Neurologic Research

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 90 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Subject is aged 18 to 90 years.
2. Subject has an NIHSS of 6 to 25.
3. Subject is able to receive the first IP within 24 hours after stroke symptoms onset.

Neuroimaging Inclusion Criteria:

1. Subject is able to undergo a contrast brain perfusion with either MRI or computed tomography (CT).
2. Subject has Target Mismatch Profile on MRI (perfusion is included) or CTP: ischemic core volume ≤70 mL, mismatch ratio ≥1.2 and mismatch volume ≥5 mL.

Exclusion Criteria:

1. Subject has been treated or intent to treat with endovascular thrombectomy and/or intravenous thrombolytic during the current AIS.
2. Subject has a pre-stroke disability (mRS ≥2).
3. Subject has large ischemic core volume >70 mL or ASPECTS ≤5.
4. Subject has symptoms of suspected subarachnoid hemorrhage.
5. Subject has imaging evidence of acute intracranial hemorrhage, intracranial tumor, arteriovenous malformations, other central nervous system lesions that could increase the risk of bleeding, or aneurysm requiring treatment.
6. Subject has significant mass effect with midline shift.
7. Subject has pre-existing medical, neurological, or psychiatric disease that would confound the neurological or functional evaluations.
8. Subject has current uncontrolled hypertension despite treatment.
9. Subject has INR >1.7 or abnormal aPTT or platelet count <100,000/mm^3.
10. Subject has received conventional heparin or new oral anticoagulants within 48 hours before the first IP administration.
11. Subject has blood glucose concentration <50 mg/dL or >400 mg/dL.
12. Subject has moderate or severe hepatic, renal, and/or active infectious disease.
13. Subject is lactating, pregnant, or planning to become pregnant during the study.
14. Subject has had history of sICH, prior AIS, myocardial infarction, or serious head trauma within 90 days before Screening.
15. Subject has had any major surgery within 90 days before Screening.
16. Subject has had a bleeding event within 21 days before Screening.
17. Subject has puncture of noncompressible vessels within 7 days before Screening.
18. Subject has participated in another investigational study and received IP within 30 days before Screening or 5 half-lives (whichever is longer).
19. In the opinion of the Investigator, the subject is not appropriate for the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: LT3001 Drug Product; Administered by intravenous infusion	Drug: LT3001 Drug Product; Administered by intravenous infusion
Placebo Comparator: Placebo; Administered by intravenous infusion	Drug: Placebo; Administered by intravenous infusion

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The Proportion of Subjects With Adverse Events (AEs), Judged to be Probably or Definitely Related to the Investigational Product (IP), Within 90 Days After the First IP Administration.	There were no subjects in either treatment group who met the predefined criteria for the primary safety endpoint: the proportion of subjects with TEAEs judged to be probably or definitely related to the IP within 90 days after the first IP administration.	within 90 days after the first IP administration

Collaborators and Investigators

• Sponsor: Lumosa Therapeutics Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): August 17, 2022
• Primary Completion (Actual): May 23, 2025
• Study Completion (Actual): May 23, 2025

Study Registration Dates

• First Submitted: May 31, 2022
• First Submitted That Met QC Criteria: May 31, 2022
• First Posted (Actual): June 3, 2022

Study Record Updates

• Last Update Posted (Actual): December 26, 2025
• Last Update Submitted That Met QC Criteria: December 9, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Stroke; Ischemic Stroke
• Other Study ID Numbers: LT3001-205

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No